Indirect Comparison Between Eltrombopag & Romiplostim

This study has been completed.
Sponsor:
Information provided by:
GlaxoSmithKline
ClinicalTrials.gov Identifier:
NCT01236014
First received: November 4, 2010
Last updated: November 3, 2011
Last verified: November 2011

November 4, 2010
November 3, 2011
August 2009
October 2009   (final data collection date for primary outcome measure)
  • Durable response: platelet count of >=50 and <400 Gi/L [ Time Frame: 6 months ] [ Designated as safety issue: No ]
  • Overall response: either a durable response or a transient platelet response [ Time Frame: 6 months ] [ Designated as safety issue: No ]
  • Durable response: platelt count of >=50 and <400 Gi/L [ Time Frame: 6 months ] [ Designated as safety issue: No ]
  • Overall response: either a durable response or a transient platelet response [ Time Frame: 6 months ] [ Designated as safety issue: No ]
Complete list of historical versions of study NCT01236014 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Indirect Comparison Between Eltrombopag & Romiplostim
Indirect Comparison of Efficacy of Treatments for Idiopathic Immune Thrombocytopenic Purpura - Review of Platelet Responses and Bleeding Events

An indirect comparison to compare the efficacy of eltrombopag versus romiplostim

An indirect analysis was conducted to evaluate the relative efficacy of eltrombopag and romiplostim using placebo as a common comparator

Observational
Time Perspective: Retrospective
Not Provided
Not Provided
Probability Sample

Identified through a systematic review: TRA102537, Kuter 2008

Thrombocytopaenia
  • Drug: Eltrombopag
    Eltrombopag & standard of care
  • Drug: Romiplostim
    Romiplostim & standard of care
  • Drug: Placebo
    Placebo & standard of care
  • Eltrombopag & standard of care
    Intervention: Drug: Eltrombopag
  • Romiplostim & standard of care
    Intervention: Drug: Romiplostim
  • Standard of care
    Intervention: Drug: Placebo
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
1
October 2009
October 2009   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Adults with ITP
  • Pre-specified treatment
  • Prospective clinical studies with at least 10 patients

Exclusion Criteria:

  • Adults with ITP for other reasons
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
NCT01236014
114014
No
Cheri Hudson; Clinical Disclosure Advisor, GSK Clinical Disclosure
GlaxoSmithKline
Not Provided
Study Director: GSK Clinical Trials GlaxoSmithKline
GlaxoSmithKline
November 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP